Zobrazeno 41 - 50
of 7 093
pro vyhledávání: ''
Autor:
Konstantin Penkov, Taofeek K. Owonikoko, Peter M. Ellis, Bruce A. Bach, Anne Sibille, Vasudha Sehgal, Choon Hee Son, Lei He, Jaimee Glasgow, Harry J.M. Groen, Junya Fujimoto, Patricia M. de Groot, Kingston Kang, Martin Dunbar, Lauren Averett Byers, Steven J. M. Gans, Dmitry Bentsion
Publikováno v:
Clinical Cancer Research, 27(14), 3884-3895. AMER ASSOC CANCER RESEARCH
Purpose: This study investigated the efficacy and safety of oral PARP inhibitor veliparib, plus carboplatin and etoposide in patients with treatment-naïve, extensive-stage small cell lung cancer (ED-SCLC). Patients and Methods: Patients were randomi
Autor:
Koichi Takahashi, Naval Daver, Sanam Loghavi, Yesid Alvarado, Rasoul Pourebrahim, Abhishek Maiti, Tapan M. Kadia, Hagop M. Kantarjian, Musa Yilmaz, Nicholas J. Short, Kunhwa Kim, Courtney D. DiNardo, Maro Ohanian, Farhad Ravandi, Koji Sasaki, Marina Konopleva, Ken Furudate, Guilin Tang, Caitlin R. Rausch
Publikováno v:
Cancer. 127:3772-3781
BACKGROUND TP53 mutation (TP53mut ) confers an adverse prognosis in acute myeloid leukemia (AML). Venetoclax with hypomethylating agents is a current standard for older patients; however, recent reports suggest that TP53mut confers resistance to vene
Autor:
Walid Shalata, Yulia Dudnik, Ashraf A-J, Keren Rouvinov, Elron Oscar, Alexander Yakobson, Margarita Toker, Ismaell Massalha
Publikováno v:
Anti-Cancer Drugs. 32:1138-1141
In the present case study, we describe a 53-year-old male with an aggressive small cell lung cancer (SCLC) that was diagnosed in January 2019. Our patient was treated as first line of systemic chemotherapy consisting of cisplatin and etoposide follow
Autor:
Marilita M Moschos, Konstantinos A A Douglas, Vivian Paraskevi Douglas, Sergios Tsakatikas, Christos Kosmas, Alexandros D Liatsos, Georgios I Papageorgiou, David G Symeonidis
Publikováno v:
Anti-Cancer Drugs. 32:1146-1149
Trastuzumab emtansine (T-DM1) is a human epidermal growth factor receptor 2 (Her2) - targeted antibody-drug conjugate that is approved for patients previously treated with trastuzumab and a taxane for Her2-positive advanced breast cancer and those wh
Autor:
Xin Li, Ting Yuan, Rui Sun, Xia Xiong, Yunxiong Wei, Hairong Lyu, Xin Jin, Ming-Feng Zhao, Wenyi Lu, Xiaoyuan He, Tongtong Sun
Publikováno v:
Cancer Science
Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are usually associated with poor outcomes, especially in high‐risk AML/MDS. Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is the only curative option for patients su
Publikováno v:
Anticancer Research. 41:3543-3560
BACKGROUND/AIM There is a lack of data concerning the surgical treatment of locally advanced squamous cell carcinoma of the uterine cervix (LACC) with neoadjuvant and adjuvant chemotherapy (NACT, ACT) as well as total mesometrial resection (TMMR). Th
Autor:
Geraldine M. Jacobson, Gary Marano, Timothy D. Eubank, Malcolm D. Mattes, Patrick C. Ma, Mohammed Almubarak, Sijin Wen
Publikováno v:
Clin Lung Cancer
INTRODUCTION/BACKGROUND: This study assessed the safety and systemic (abscopal) response from the addition of local stereotactic body radiation therapy (SBRT) to checkpoint inhibitor (CPI) immunotherapy in patients with metastatic non-small cell lung
Autor:
Sophie Alberdine Kurk, Bart A. W. Jacobs, Jacob Hendrik Beijnen, Neeltje Steeghs, Thomas P.C. Dorlo, Laura Molenaar-Kuijsten, Anne Maria May, Alwin Dagmar Redmar Huitema
Publikováno v:
Cancer medicine, 10(14), 4781-4789. John Wiley and Sons Ltd
Cancer Medicine
Cancer Medicine, Vol 10, Iss 14, Pp 4781-4789 (2021)
Cancer Medicine
Cancer Medicine, Vol 10, Iss 14, Pp 4781-4789 (2021)
Background A low skeletal muscle mass (SMM) has been associated with increased toxicity and shorter survival in cancer patients treated with capecitabine, an oral prodrug of 5‐fluorouracil (5‐FU). Capecitabine and its metabolites are highly water
Autor:
Donald P. Bottaro, Ralph E. Parchment, Larry Rubinstein, Barry C. Johnson, Woondong Jeong, Young H. Lee, Khanh T. Do, Apurva K. Srivastava, James H. Doroshow, John Wright, Alice P. Chen, S. Kummar, Tony Navas, Andrea Regier Voth, Fabiola Cecchi, Sook Ryun Park
Publikováno v:
Investigational New Drugs
The vascular endothelial growth factor (VEGF)/VEGFR and hepatocyte growth factor (HGF)/c-MET signaling pathways act synergistically to promote angiogenesis. Studies indicate VEGF inhibition leads to increased levels of phosphorylated c-MET, bypassing
Autor:
Felipe Suarez, Maya Belhadj, Etienne Lengliné, Olivier Kosmider, Anne-Ségolène Cottereau, Vahid Asnafi, Patricia Palmic, Lise Willems, Adrien Contejean, Didier Bouscary, Barbara Burroni, Diane Damotte
Publikováno v:
Anti-Cancer Drugs. 32:1118-1122
Myeloid sarcomas represent a heterogeneous group of diseases with a tumoral presentation of acute myeloid leukemia. The clinical presentation of these hematologic cancers is typically aggressive and thus rapidly fatal in the absence of treatment, whi